The Dr. Doug Show cover image

Can This New Compound, AP503, Actually Reverse Bone Loss? (Doctor Explains)

The Dr. Doug Show

00:00

Where AP503 Is in the Drug Pipeline

Dr. Doug Lucas outlines that AP503 is preclinical, with no human trials and a typical 10% or lower success rate to approval.

Play episode from 03:33
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app